Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.
Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, Coriat R, Goldwasser F. Tlemsani C, et al. Among authors: huillard o. Target Oncol. 2011 Dec;6(4):253-8. doi: 10.1007/s11523-011-0201-x. Epub 2011 Nov 17. Target Oncol. 2011. PMID: 22090260 Review.
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O, Boissier E, Blanchet B, Thomas-Schoemann A, Cessot A, Boudou-Rouquette P, Durand JP, Coriat R, Giroux J, Alexandre J, Vidal M, Goldwasser F. Huillard O, et al. Expert Opin Drug Saf. 2014 May;13(5):663-73. doi: 10.1517/14740338.2014.907270. Epub 2014 Apr 3. Expert Opin Drug Saf. 2014. PMID: 24693873 Review.
Sorafenib in thyroid cancer patients: learning from toxicity.
Huillard O, Blanchet B, Boudou-Rouquette P, Thomas-Schoemann A, Wassermann J, Goldwasser F. Huillard O, et al. Oncologist. 2014 Aug;19(8):e3. doi: 10.1634/theoncologist.2014-0156. Epub 2014 Jul 22. Oncologist. 2014. PMID: 25052452 Free PMC article.
[Biotherapies in metastatic colorectal cancers in 2014].
Jouinot A, Coriat R, Huillard O, Goldwasser F. Jouinot A, et al. Among authors: huillard o. Presse Med. 2014 Oct;43(10 Pt 1):1056-66. doi: 10.1016/j.lpm.2014.03.028. Epub 2014 Jul 24. Presse Med. 2014. PMID: 25065664 Review. French.
Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.
Arrondeau J, Huillard O, Tlemsani C, Cessot A, Boudou-Rouquette P, Blanchet B, Thomas-Schoemann A, Vidal M, Tigaud JM, Durand JP, Alexandre J, Goldwasser F. Arrondeau J, et al. Among authors: huillard o. Expert Opin Investig Drugs. 2015 May;24(5):673-87. doi: 10.1517/13543784.2015.1005736. Epub 2015 Jan 20. Expert Opin Investig Drugs. 2015. PMID: 25599887 Review.
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
Tlemsani C, Huillard O, Arrondeau J, Boudou-Rouquette P, Cessot A, Blanchet B, Thomas-Schoemann A, Coriat R, Durand JP, Giroux J, Alexandre J, Goldwasser F. Tlemsani C, et al. Among authors: huillard o. Expert Opin Drug Metab Toxicol. 2015 May;11(5):785-94. doi: 10.1517/17425255.2015.1030392. Epub 2015 Mar 25. Expert Opin Drug Metab Toxicol. 2015. PMID: 25809423 Review.
91 results